Freestone Grove Partners LP purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 439,138 shares of the medical instruments supplier's stock, valued at approximately $99,627,000. Becton, Dickinson and Company comprises 1.2% of Freestone Grove Partners LP's investment portfolio, making the stock its 5th largest position. Freestone Grove Partners LP owned approximately 0.15% of Becton, Dickinson and Company as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of the stock. Bank of Jackson Hole Trust bought a new position in Becton, Dickinson and Company during the 4th quarter valued at $25,000. Sierra Ocean LLC purchased a new position in Becton, Dickinson and Company during the fourth quarter worth about $29,000. Picton Mahoney Asset Management boosted its holdings in Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after purchasing an additional 54 shares during the last quarter. Hopwood Financial Services Inc. purchased a new stake in Becton, Dickinson and Company in the 4th quarter valued at about $39,000. Finally, Versant Capital Management Inc lifted its position in shares of Becton, Dickinson and Company by 54.1% during the 4th quarter. Versant Capital Management Inc now owns 208 shares of the medical instruments supplier's stock worth $47,000 after buying an additional 73 shares in the last quarter. Institutional investors own 86.97% of the company's stock.
Becton, Dickinson and Company Price Performance
Shares of Becton, Dickinson and Company stock traded down $1.79 on Tuesday, hitting $165.21. 1,090,365 shares of the company traded hands, compared to its average volume of 1,817,592. Becton, Dickinson and Company has a 12-month low of $164.72 and a 12-month high of $251.99. The firm's 50-day simple moving average is $213.55 and its 200 day simple moving average is $224.96. The company has a market cap of $47.44 billion, a P/E ratio of 27.47, a P/E/G ratio of 1.63 and a beta of 0.31. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The company had revenue of $5.27 billion during the quarter, compared to analysts' expectations of $5.35 billion. During the same quarter in the prior year, the company earned $3.17 EPS. The firm's revenue was up 4.5% on a year-over-year basis. Analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.
Becton, Dickinson and Company declared that its Board of Directors has initiated a share repurchase plan on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company's board of directors believes its stock is undervalued.
Becton, Dickinson and Company Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 79.39%.
Insider Transactions at Becton, Dickinson and Company
In related news, EVP Michael David Garrison sold 479 shares of the firm's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total value of $94,497.12. Following the completion of the sale, the executive vice president now owns 4,887 shares of the company's stock, valued at $964,107.36. This trade represents a 8.93 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bertram L. Scott sold 700 shares of the business's stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $227.99, for a total transaction of $159,593.00. Following the transaction, the director now directly owns 36,033 shares in the company, valued at approximately $8,215,163.67. The trade was a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,578 shares of company stock worth $795,986. Insiders own 0.36% of the company's stock.
Wall Street Analysts Forecast Growth
BDX has been the subject of several recent analyst reports. Wells Fargo & Company lowered Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a report on Thursday, May 1st. Morgan Stanley lowered their target price on Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating on the stock in a research note on Tuesday. StockNews.com lowered shares of Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Friday. Piper Sandler cut shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and dropped their target price for the company from $260.00 to $185.00 in a research note on Friday. Finally, The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target for the company. in a research note on Friday. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has an average rating of "Hold" and a consensus price target of $231.44.
Read Our Latest Report on BDX
Becton, Dickinson and Company Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Read More
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
